Tryptophan-containing dipeptides are bioavailable and inhibit plasma human angiotensin-converting enzyme in vivo

International Dairy Journal

Volumn 52, Issue , 2016, Pages 107-114

  Kaiser, Susanne ^a   Martin, Melanie ^b   Lunow, Diana ^a   Rudolph, Steffi ^a   Mertten, Stephanie ^a   Möckel, Ulrike ^a   Deußen, Andreas ^b   Henle, Thomas ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CARDIOVASCULAR SYSTEM; PEPTIDES;

ACE ACTIVITIES; ANGIOTENSIN-CONVERTING ENZYME; BENEFICIAL EFFECTS; BIOAVAILABLE; ENZYMATIC HYDROLYSATES; HUMAN VOLUNTEERS; PLASMA CONCENTRATION; WHEY PROTEINS;

ENZYMES;

EID: 84945360330     PISSN: 09586946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idairyj.2015.09.004     Document Type: Article

References (52)

1. Boelsma E., Kloek J. IPP-rich milk protein hydrolysate lowers blood pressure in subjects with stage 1 hypertension, a randomized controlled trial. Nutrition Journal 2010, 9:52.
2. Buch P., Rasmussen S., Abildstrom S.Z., Kober L., Carlsen J., Torp-Pedersen C. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. European Heart Journal 2005, 26:145-152.
3. Campbell D., Kladis A., Duncan A. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994, 23:439-449.
4. Cicero A.F.G., Rosticci M., Gerocarni B., Bacchelli S., Veronesi M., Strocchi E., et al. Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial. Hypertension Research: Official Journal of the Japanese Society of Hypertension 2011, 34:1035-1040.
5. DIN DIN 38402-51. Deutsche Einheitsverfahren zur Wasser-, Abwasser und Schlammuntersuchung; Allgemeine Angaben (Gruppe A); Kalibrierung von Analysenverfahren, Auswertung von Analysenergebnissen und lineare Kalibrierfunktionen für die Bestimmung von Verfahrenskenngrößen 1986, 05.
6. DIN DIN 32645. Chemische Analytik - Nachweis-, Erfassungs- und Bestimmungsgrenze unter Wiederholbedingungen - Begriffe, Verfahren, Auswertung 2008, 11.
7. Ehlers M.R., Gordon K., Schwager S.L., Sturrock E.D. Shedding the load of hypertension: the proteolytic processing of angiotensin-converting enzyme. South African Medical Journal 2012, 102:461-464.
8. Ervin G., Erdös M. Conversion of angiotensin I to angiotensin II. American Journal of Medicine 1976, 60:749-759.
9. Fitzgerald R.J., Murray B.A., Walsh D.J. The emerging role of dairy proteins and bioactive peptides in nutrition and health. Journal of Nutrition 2004, 134:980S-988S.
10. Foltz M., Meynen E.E., Bianco V., van Platerink C., Koning T.M., Kloek J. Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation. Journal of Nutrition 2007, 137:953-958.
11. Fujita H., Yamagami T., Ohshima K. Effects of an ace-inhibitory agent, katsuobushi oligopeptide, in the spontaneously hypertensive rat and in borderline and mildly hypertensive subjects. Nutrition Research 2001, 21:1149-1158.
12. Guang C., Milani F., Shang J., Zhang H. New evidence for production, biochemistry and in vitro and in vivo effects of tripeptides Val-Pro-Pro and Ile-Pro-Pro. Journal of Food, Agriculture and Environment 2012, 10:32-39.
13. Imanishi T., Tsujioka H., Akasaka T. Endothelial progenitor cells dysfunction and senescence: contribution to oxidative stress. Current Cardiology 2008, 4:275-286.
14. Jauhiainen T., Korpela R. Milk peptides and blood pressure. Journal of Nutrition 2007, 137:825S-829S.
15. Jauhiainen T., Rönnback M., Vapaatalo H., Wuolle K., Kautiainen H., Groop P.-H., et al. Long-term intervention with Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects. European Journal of Clinical Nutrition 2010, 64:424-431.
16. Jauhiainen T., Wuolle K., Vapaatalo H., Kerojoki O., Nurmela K., Lowrie C., et al. Oral absorption, tissue distribution and excretion of a radiolabelled analog of a milk-derived antihypertensive peptide, Ile-Pro-Pro, in rats. International Dairy Journal 2007, 17:1216-1223.
17. Kawasaki T., Seki E., Osajima K., Yoshida M., Asada K., Matsui T., et al. Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. Journal of Human Hypertension 2000, 14:519-523.
18. Kohmura M., Nio N., Ariyoshi Y. Inhibition of angiotensin-converting enzyme by synthetic peptide fragments of various beta-caseins. Agricultural and Biological Chemistry 1990, 54:1101-1102.
19. Langner A., Borchert H.-H., Mehnert W. Biopharmazie: Pharmakokinetik - Bioverfügbarkeit - Biotransformation 2011, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, Germany. 4th ed.
20. Li G.-H., Le G.-W., Shi Y.-H., Shrestha S. Angiotensin I-converting enzyme inhibitory peptides derived from food proteins and their physiological and pharmacological effects. Nutrition Research 2004, 24:469-486.
21. Lühder F., Lee D.H., Gold R., Stegbauer J., Linker R.A. Small but powerful: short peptide hormones and their role in autoimmune inflammation. Journal of Neuroimmunology 2009, 217:1-7.
22. Lunow D., Kaiser S., Brückner S., Gotsch A., Henle T. Selective release of ACE-inhibiting tryptophan-containing dipeptides from food proteins by enzymatic hydrolysis. European Food Research and Technology 2013, 237:27-37.
23. Lunow D., Kaiser S., Rückriemen J., Pohl C., Henle T. Tryptophan-containing dipeptides are C-domain selective inhibitors of angiotensin converting enzyme. Food Chemistry 2015, 166:596-602.
24. Malaguti M., Dinelli G., Leoncini E., Bregola V., Bosi S., Cicero A.F.G., et al. Bioactive peptides in cereals and legumes: agronomical, biochemical and clinical aspects. International Journal of Molecular Sciences 2014, 15:21120-21135.
25. Martin M., Wellner A., Ossowski I., Henle T. Identification and quantification of inhibitors for Angiotensin-converting enzyme in hypoallergenic infant milk formulas. Journal of Agricultural and Food Chemistry 2008, 56:6333-6338.
26. Matsui T., Imamura M., Oka H., Osajima K., Kimoto K.-I., Kawasaki T., et al. Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats. Journal of Peptide Science 2004, 10:535-545.
27. Matsui T., Tamaya K., Seki E., Osajima K., Matsumoto K., Kawasaki T. Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system. Clinical and Experimental Pharmacology and Physiology 2002, 29:204-208.
28. Meisel H. Overview on milk protein-derived peptides. International Dairy Journal 1998, 8:363-373.
29. Meisel H., Pentzien A. Transepithelial transport and stability in blood serum of angiotensin-I-converting enzyme inhibitory dipeptides. Zeitschrift für Naturforschung 2008, 63:451-459.
30. Nakamura Y., Yamamoto N., Sakai K., Okubo A., Yamazaki S., Takano T. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. Journal of Dairy Science 1995, 78:777-783.
31. Nongonierma A.B., FitzGerald R.J. Milk proteins as a source of tryptophan-containing bioactive peptides. Food and Function 2015, 6:2115-2127.
32. Ohsawa K., Satsu H., Ohki K., Enjoh M., Takano T., Shimizu M. Producibility and digestibility of antihypertensive β-casein tripeptides, Val-Pro-Pro and Ile-Pro-Pro, in the gastrointestinal tract. Journal of Agricultural and Food Chemistry 2008, 56:854-858.
33. Pignone A., Del Rosso A., Brosnihan K.B., Perfetto F., Livi R., Fiori G., et al. Reduced circulating levels of angiotensin-(1-7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Annals of the Rheumatic Diseases 2007, 66:1305-1310.
34. Pinhati R., Polonini H., Brandão M. Quantification of tryptophan in plasma by high performance liquid chromatography. Química Nova 2012, 35:623-626.
35. Saida K., Mitsui Y. Structure of the precursor for vasoactive intestinal contractor (VIC): its comparison with those of endothelin-1 and endothelin-3. Journal of Cardiovascular Pharmacology 1991, 17(Suppl. 7):S55-S58.
36. Saito T. Antihypertensive peptides derived from bovine casein and whey proteins. Advances in Experimental Medicine and Biology 2008, 606:295-317.
37. Saito Y., Nakamura K., Kawato A., Imayasu S. Angiotensin-I converting enzyme-inhibitors in sake and its by-products. Nippon Nogeikagaku Kaishi-Journal of the Japan Society for Bioscience Biotechnology and Agrochemistry 1992, 66:1081-1087.
38. Samaranayaka A.G.P., Li-Chan E.C.Y. Food-derived peptidic antioxidants: a review of their production, assessment, and potential applications. Journal of Functional Foods 2011, 3:229-254.
39. Santos E.L., de Picoli Souza K., da Silva E.D., Batista E.C., Martins P.J.F., D'Almeida V., et al. Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochemical Pharmacology 2009, 78:951-958.
40. Seki E., Osajima K., Matsufuji H. Val-Tyr, and angiotensin I converting enzyme inhibitor from sardines that have resistance to gastrointestinal proteases. Nippon Nogeikagaku Kaishi-Journal of the Japan Society for Bioscience Biotechnology and Agrochemistry 1995, 69:1013-1020.
41. Shah V.P., Midha K.K., Findlay J.W., Hill H.M., Hulse J.D., McGilveray I.J., et al. Bioanalytical method validation-a revisit with a decade of progress. Pharmaceutical Research 2000, 17:1551-1557.
42. Skeggs L., Kahn J., Shumway N. The preparation and function of the hypertensin-converting enzyme. Journal of Experimental Medicine 1956, 103:295-299.
43. Usinger L., Jensen L.T., Flambard B., Linneberg A., Ibsen H. The antihypertensive effect of fermented milk in individuals with prehypertension or borderline hypertension. Journal of Human Hypertension 2010, 24:678-683.
44. Van Platerink C.J., Janssen H.-G.M., Horsten R., Haverkamp J. Quantification of ACE inhibiting peptides in human plasma using high performance liquid chromatography-mass spectrometry. Journal of Chromatography B 2006, 830:151-157.
45. Van der Pijl P.C., Kies A.K., Ten Have G.A., Duchateau G.S., Deutz N.E. Pharmacokinetics of proline-rich tripeptides in the pig. Peptides 2008, 29:2196-2202.
46. Van der Zander K., Jäkel M., Bianco V., Koning M.M.G. Fermented lactotripeptides-containing milk lowers daytime blood pressure in high normal-to-mild hypertensive subjects. Journal of Human Hypertension 2008, 22:804-806.
47. Vermeirssen V., Camp J.Van, Verstraete W. Bioavailability of angiotensin I converting enzyme inhibitory peptides. British Journal of Nutrition 2004, 92:357-366.
48. Weisinger R.S., Stanley T.K., Begg D.P., Weisinger H.S., Spark K.J., Jois M. Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiology and Behavior 2009, 98:192-197.
49. Wuerzner G., Peyrard S., Blanchard A., Lalanne F., Azizi M. The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans. Journal of Hypertension 2009, 27:1404-1409.
50. Yao J., Dougherty G., Reddy R., Keshavan M., Montrose D., Matson W., et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Molecular Psychiatry 2010, 15:938-953.
51. Yokoyama K. Peptide inhibitors for angiotensin I-converting enzyme from thermolysin digest of dried bonito. Bioscience, Biotechnology, and Biochemistry 1992, 56:1541-1545.
52. Zhen Q., Xu B., Ma L., Tian G., Tang X., Ding M. Simultaneous determination of tryptophan, kynurenine and 5-hydroxytryptamine by HPLC: application in uremic patients undergoing hemodialysis. Clinical Biochemistry 2011, 44:226-230.